Effect of nicotinic acid/Laropiprant in the Lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype

Metabolism: Clinical and Experimental

Volumn 63, Issue 3, 2014, Pages 365-371

  Cenarro, Ana ^a   Puzo, José ^b   Ferrando, Juan ^c   Mateo Gallego, Rocío ^a   Bea, Ana M ^a   Calmarza, Pilar ^a   Jarauta, Estíbaliz ^a   Civeira, Fernando ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL SAN JORGE   (Spain)

^c HOSPITAL ROYO VILLANOVA   (Spain)

Author keywords

Clinical trial; Genotype; Lipoprotein(a); LPA; Nicotinic acid

Indexed keywords

CLINICAL TRIAL; GENOTYPE; LIPOPROTEIN(A); LPA; NICOTINIC ACID;

APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; GENOTYPE; HUMANS; INDOLES; LIPOPROTEIN(A); LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; NIACIN; POLYMORPHISM, GENETIC; TRIGLYCERIDES;

EID: 84894061368     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.10.014     Document Type: Article

References (34)

1. J.W. Gaubatz, C. Heideman, and A.M. Gotto Jr. et al. Human plasma lipoprotein [a]. Structural properties J Biol Chem 258 7 1983 4582 4589
2. J.B. Dubé, M.B. Boffa, R.A. Hegele, and M.L. Koschinsky Lipoprotein(a): more interesting than ever after 50 years Curr Opin Lipidol 23 2 2012 133 140
3. Emerging Risk Factors Collaboration S. Erqou, and S. Kaptoge et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 4 2009 412 423
4. P.R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard Genetically elevated lipoprotein(a) and increased risk of myocardial infarction JAMA 301 22 2009 2331 2339
5. K.M. Kostner, W. März, and G.M. Kostner When should we measure lipoprotein (a)? Eur Heart J 34 42 2013 3268 3276
6. D.J. Grainger, P.R. Kemp, and A.C. Liu et al. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice Nature 370 6489 1994 460 462
7. S. Tsimikas, Z. Mallat, and P.J. Talmud et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events J Am Coll Cardiol 56 12 2010 946 955
8. J.W. McLean, J.E. Tomlinson, and W.J. Kuang et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen Nature 330 6144 1987 132 137
9. E. Boerwinkle, C.C. Leffert, and J. Lin et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations J Clin Invest 90 1 1992 52 60
10. L. Berglund, and R. Ramakrishnan Lipoprotein(a): an elusive cardiovascular risk factor Arterioscler Thromb Vasc Biol 24 12 2004 2219 2226
11. G. Utermann The mysteries of lipoprotein(a) Science 246 4932 1989 904 910
12. R. Clarke, J.F. Peden, and J.C. Hopewell et al; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease N Engl J Med 361 26 2009 2518 2528
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 25 2002 3143 3421
14. A. Gurakar, J.M. Hoeg, and G. Kostner et al. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment Atherosclerosis 57 2-3 1985 293 301
15. M. Seed, B. O'Connor, and N. Perombelon et al. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover Atherosclerosis 101 1 1993 61 68
16. A.M. Scanu, and R. Bamba Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations Am J Cardiol 101 8A 2008 44B 47B
17. S. Frank, K. Krasznai, and S. Durovic et al. High-level expression of various apolipoprotein(a) isoforms by «transferrinfection»: the role of kringle IV sequences in the extracellular association with low-density lipoprotein Biochemistry 33 40 1994 12329 12339
18. J.F. Paolini, Y.B. Mitchel, and R. Reyes et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia Am J Cardiol 101 5 2008 625 630
19. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 17 2013 1279 1291
20. M. Solanas-Barca, I. de Castro-Orós, and R. Mateo-Gallego et al. Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia Atherosclerosis 222 2 2012 449 455
21. M.B. Lanktree, C. Rajakumar, and J.H. Brunt et al. Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR J Lipid Res 50 4 2009 768 772
22. B.G. Nordestgaard, M.J. Chapman, and K. Ray et al; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 31 23 2010 2844 2853
23. J. Hoover-Plow, and M. Huang Lipoprotein(a) metabolism: potential sites for therapeutic targets Metabolism 62 4 2013 479 491
24. E.M. Roth, J.M. McKenney, and C. Hanotin et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 20 2012 1891 1900
25. I. Gouni-Berthold, and H.K. Berthold Antisense oligonucleotides for the treatment of dyslipidemia Curr Pharm Des 17 9 2011 950 960
26. C.P. Cannon, S. Shah, and H.M. Dansky et al. Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 25 2010 2406 2415
27. H.K. Berthold, and I. Gouni-Berthold Hyperlipoproteinemia(a): clinical significance and treatment options Atheroscler Suppl 14 1 2013 1 5
28. A.L. White, J.E. Hixson, D.L. Rainwater, and R.E. Lanford Molecular basis for «null» lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon J Biol Chem 269 12 1994 9060 9066
29. N. Artemeva, M. Safarova, and M. Ezhov et al. Niacin efficacy and safety in apparently healthy men with lipoprotein(a) excess Program of the 81st European Atherosclerosis Society Congress, Lyon, France 2013 87 [abstract]
30. I. Chennamsetty, K.M. Kostner, and T. Claudel et al. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice J Lipid Res 53 11 2012 2405 2412
31. R.B. Goldberg, and T.A. Jacobson Effects of niacin on glucose control in patients with dyslipidemia Mayo Clin Proc 83 4 2008 470 478
32. J.J. Kelly, J.A. Lawson, and L.V. Campbell et al. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects J Hum Hypertens 14 9 2000 567 572
33. A.M. Poynten, S.K. Gan, and A.D. Kriketos et al. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content Metabolism 52 6 2003 699 704
34. B.A. Connolly, D.P. O'Connell, and S. Lamon-Fava et al. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans Metabolism 2013 10.1016/j.metabol.2013.08.001